Therapeutic application of histone deacetylase inhibitors for stroke

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2011, Pages 138-149

  Lv, Lei ^a   Tang, Yu Ping ^a   Han, Xiang ^a   Wang, Xin ^b   Dong, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Histone deacetylase inhibitors; Stroke

Indexed keywords

4 PHENYLBUTYRIC ACID; AMPA RECEPTOR; ANTINEOPLASTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BUTYRIC ACID; ENTINOSTAT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIN; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL MOTILITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CUTANEOUS T CELL LYMPHOMA; DEGENERATIVE DISEASE; DRUG BINDING; DRUG MECHANISM; DRUG PENETRATION; ENDOTHELIUM CELL; EXCITOTOXICITY; EXPERIMENTAL AUTOIMMUNE NEURITIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; LEUKOCYTE; MICROGLIA; NERVOUS SYSTEM DEVELOPMENT; NEURITIS; NEUROPROTECTION; NONHUMAN; NUCLEOSOME; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); RETINA ISCHEMIA; REVIEW; STROKE; TRAUMATIC BRAIN INJURY; ULCERATIVE COLITIS;

EID: 79959287715     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152411796011330     Document Type: Review

References (119)

1. Lo, E.H.; Dalkara, T.; Moskowitz, M.A. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci., 2003, 4(5), 399-415.
2. Khaja, A.M.; Grotta, J.C. Established treatments for acute ischaemic stroke. Lancet, 2007, 369(9558), 319-330.
3. Moskowitz, M.A.; Lo, E.H.; Iadecola, C. The Science of Stroke: Mechanisms in Search of Treatments. Neuron, 2010, 67(2), 181-198.
4. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De Simone, G.; Ferguson, T.B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; Mcdermott, M.; Meigs, J.; Mozaffarian, D.; Nichol, G.; O'donnell, C.; Roger, V.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.; Wylie-Rosett, J.; Hong, Y. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2009, 119(3), 480-486.
5. Hacke W. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 - The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Cerebrovasc. Dis., 2008, 25(5), 457-507.
6. Yuan, J.Y. Neuroprotective strategies targeting apoptotic and necrotic cell death for stroke. Apoptosis, 2009, 14(4), 469-477.
7. Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128(4), 693-705.
8. Carey, N.; La Thangue, N.B. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol., 2006, 6(4), 369-375.
9. Abel, T.; Zukin, R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol., 2008, 8(1), 57-64.
10. Chuang, D.-M.; Leng, Y.; Marinova, Z.; Kim, H.-J.; Chiu, C.-T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci., 2009, 32(11), 591-601.
11. Langley, B.; Gensert, J.M.; Beal, M.F.; Ratan, R.R. Remodeling chromatin and stress resistance in the central nervous system: Histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord., 2005, 4(1), 41-50.
12. Kazantsev, A.G.; Thompson, L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov., 2008, 7(10), 854-868.
13. Ren, M.; Leng, Y.; Jeong, M.; Leeds, P.R.; Chuang, D.M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem., 2004, 89(6), 1358-1367.
14. Sinn, D.I.; Kim, S.J.; Chu, K.; Jung, K.H.; Lee, S.T.; Song, E.C.; Kim, J.M.; Park, D.K.; Lee, S.K.; Kim, M.; Roh, J.K. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol. Dis., 2007, 26(2), 464-472.
15. Yildirim, F.; Gertz, K.; Golo, K.; Harms, C.; Fink, K.B.; Meisel, A.; Endres, M. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp. Neurol., 2008, 210(2), 531-542.
16. Faraco, G.; Pancani, T.; Formentini, L.; Mascagni, P.; Fossati, G.; Leoni, F.; Moroni, F.; Chiarugi, A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol., 2006, 70(6), 1876-1884.
17. Gelato, K.A.; Fischle, W. Role of histone modifications in defining chromatin structure and function. Biol. Chem., 2008, 389(4), 353-363.
18. Itoh, Y.; Suzuki, T.; Miyata, N. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des., 2008, 14(6), 529-544.
19. Echaniz-Laguna, A.; Bousiges, O.; Loeffler, J.P.; Boutillier, A.L. Histone deacetylase inhibitors: Therapeutic agents and research tools for deciphering motor neuron diseases. Curr. Med. Chem., 2008, 15(13), 1263-1273.
20. Bolger, T.A.; Yao, T.P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci., 2005, 25(41), 9544-9553.
21. Chawla, S.; Vanhoutte, P.; Arnold, F.J.L.; Huang, C.L.H.; Bading, H. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J. Neurochem., 2003, 85(1), 151-159.
22. Gurvich, N.; Tsygankova, O.M.; Meinkoth, J.L.; Kein, P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res., 2004, 64(3), 1079-1086.
23. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.F.; Yao, T.P. HDAC6 is a microtubule-associated deacetylase. Nature, 2002, 417(6887), 455-458.
24. Saha, R.N.; Pahan, K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ., 2006. 13(4), 539-550.
25. Kim, H.J.; Leeds, P.; Chuang, D.M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J. Neurochem., 2009, 110(4), 1226-1240.
26. Phiel, C.J.; Zhang, F.; Huang, E.Y.; Guenther, M.G.; Lazar, M.A.; Klein, P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem., 2001, 276(39), 36734-36741.
27. Nalivaeva, N.N.; Belyaev, N.D.; Turner, A.J. Sodium valproate: an old drug with new roles. Trends Pharmacol. Sci., 2009, 30(10), 509-514.
28. Fukuchi, M.; Nii, T.; Ishimaru, N.; Minamino, A.; Hara, D.; Takasaki, I.; Tabuchi, A.; Tsuda, M. Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions. Neurosci. Res., 2009, 65(1), 35-43.
29. Kanai, H.; Sawa, A.; Chen, R.W.; Leeds, P.; Chuang, D.M. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J., 2004, 4(5), 336-344.
30. Chen, P.S.; Wang, C.C.; Bortner, C.D.; Peng, G.S.; Wu, X.; Pang, H.; Lu, R.B.; Gean, P.W.; Chuang, D.M.; Hong, J.S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience, 2007, 149(1), 203-212.
31. Jeong, M.R.; Hashimoto, R.; Senatorov, V.V.; Fujimaki, K.; Ren, M.; Lee, M.S.; Chuang, D.M. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett., 2003, 542(1-3), 74-78.
32. Kim, H.J.; Rowe, M.; Ren, M.; Hong, J.S.; Chen, P.S.; Chuang, D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: Multiple mechanisms of action. J. Pharmacol. Exp. Ther., 2007, 321(3), 892-901.
33. Zhang, B.; West, E.J.; Van, K.C.; Gurkoff, G.G.; Zhou, J.; Zhang, X.M.; Kozikowski, A.P.; Lyeth, B.G. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res., 2008, 1226, 181-191.
34. Zhang, Z.; Zhang, Z.Y.; Fauser, U.; Schluesener, H.J. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell. Mol. Life Sci., 2008, 65(24), 4055-4065.
35. Cui, S.S.; Yang, C.P.; Bowen, R.C.; Bai, O.; Li, X.M.; Jiang, W.; Zhang, X. Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats. Brain Res., 2003, 975(1-2), 229-236.
36. Dash P.K.; Orsi, S.A.; Zhang, M.; Grill, R.J.; Pati, S.; Zhao, J.; Moore, A.N. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One, 2010, 5(6), e11383.
37. Yuan, P.X.; Huang, L.D.; Jiang, Y.M.; Gutkind, J.S.; Manji, H.K.; Chen, G. The mood stabilizer valproic acid activates mitogenactivated protein kinases and promotes neurite growth. J. Biol. Chem., 2001, 276(34), 31674-31683.
38. Biermann, J.; Grieshaber, P.; Goebel, U.; Martin, G.; Thanos, S.; Di Giovanni, S.; Lagreze, W.A. Valproic Acid-Mediated Neuroprotection and Regeneration in Injured Retinal Ganglion Cells. Invest. Ophthalmol. Vis. Sci., 2010, 51(1), 526-534.
39. Yamauchi, J.; Miyamoto, Y.; Kusakawa, S.; Torii, T.; Mizutani R.; Sanbe, A.; Nakajima H.; Kiyokawa N.; Tanoue, A. Neurofibromatosis 2 tumor suppressor, the gene induced by valproic acid, mediates neurite outgrowth through interaction with paxillin. Exp. Cell Res., 2008, 314(11-12), 2279-2288.
40. Yamauchi, J.; Torii, T.; Kusakawa, S.; Sanbe, A.; Nakamura, K.; Takashima, S.; Hamasaki, H.; Kawaguchi, S.; Miyamoto, Y.; Tanoue, A. The Mood Stabilizer Valproic Acid Improves Defective Neurite Formation Caused by Charcot-Marie-Tooth Disease- Associated Mutant Rab7 Through the JNK Signaling Pathway. J. Neurosci. Res., 2010, 88(14), 3189-3197.
41. Dragunow, M.; Greenwood, J.M.; Cameron, R.E.; Narayan, P.J.; O'carroll, S.J.; Pearson, A.G.; Gibbons, H.M. Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience, 2006, 140(4), 1149-1156.
42. Kim, B.; Castro, L.M.R.; Jawed, S.; Niles, L.P. Clinically relevant concentrations of valproic acid modulate melatonin MT1 receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. Eur. J. Pharmacol., 2008, 589(1-3), 45-48.
43. Castro, L.M.R.; Gallant, M.; Niles, L.P. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J. Neurochem., 2005, 95(5), 1227-1236.
44. Wang, X. The Antiapoptotic Activity of Melatonin in Neurodegenerative Diseases. CNS Neurosci. Ther., 2009, 15(4), 345-357.
45. Wang, X.; Figueroa, B.E.; Stavrovskaya, I.G.; Zhang, Y.; Sirianni, A.C.; Zhu, S.; Day, A.L.; Kristal, B.S.; Friedlander, R.M. Methazolamide and Melatonin Inhibit Mitochondrial Cytochrome C Release and Are Neuroprotective in Experimental Models of Ischemic Injury. Stroke, 2009, 40(5), 1877-1885.
46. Vernia, P.; Monteleone, G.; Grandinetti, G.; Villotti, G.; Di Giulio, E.; Frieri, G.; Marcheggiano, A.; Pallone, F.; Caprilli, R.; Torsoli, A. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis - Randomized, double-blind, placebo-controlled pilot study. Dig. Dis. Sci., 2000, 45(5), 976-981.
47. Kaneko, F.; Saito, H.; Saito, Y.; Wakabayashi, K.; Nakamoto, N.; Tada, S.; Suzuki, H.; Tsunematsu, S.; Kumagai, N.; Ishii, H. Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int. J. Oncol., 2004, 24(4), 837-845.
48. Minamiyama, M.; Katsuno, M.; Adachi, H.; Waza, M.; Sang, C.; Kobayashi, Y.; Tanaka, F.; Doyu, M.; Inukai, A.; Sobue, G. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet., 2004, 13(11), 1183-1192.
49. Ying, M.Y.; Xu, R.; Wu, X.H.; Zhu, H.X.; Zhuang, Y.; Han, M.; Xu, T. Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J. Biol. Chem., 2006, 281(18), 12580-12586.
50. Ferrante, R.J.; Kubilus, J.K.; Lee, J.; Ryu, H.; Beesen, A.; Zucker, B.; Smith, K.; Kowall, N.W.; Ratan, R.R.; Luthi-Carter, R.; Hersch, S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci., 2003, 23(28), 9418-9427.
51. Kidd, S.K.; Schneider, J.S. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res, 2010, 1354, 172-178.
52. Guerron A.D.; Rawat, R.; Sali, A.; Spurney, C.F.; Pistilli, E.; Cha, H.-J.; Pandey, G.S.; Gernapudi, R.; Francia, D.; Farajian, V.; Escolar, D.M.; Bossi, L.; Becker, M.; Zerr, P.; De La Porte, S.; Gordish-Dressman, H.; Partridge, T.; Hoffman, E.P.; Nagaraju, K. Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the mdx Mouse Model of Duchenne Muscular Dystrophy. PLoS One, 2010, 5(6), e11220.
53. Lee, B.; Rhead, W.; Diaz, G.A.; Scharschmidt, B.F.; Mian, A.; Shchelochkov, O.; Marier, J.F.; Beliveau, M.; Mauney, J.; Dickinson, K.; Martinez, A.; Gargosky, S.; Mokhtarani, M.; Berry, S.A. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol. Genet. Metab., 2010, 100(3), 221-8.
54. Ryu, H.; Smith, K.; Camelo, S.I.; Carreras, I.; Lee, J.; Iglesias, A.H.; Dangond, F.; Cormier, K.A.; Cudkowicz, M.E.; Brown, R.H.; Ferrante, R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem., 2005, 93(5), 1087-1098.
55. Yam, G.H.T.; Gaplovska-Kysela, K.; Zuber, C.; Roth, J. Sodium 4- phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest. Ophthalmol. Vis. Sci., 2007, 48(4), 1683-1690.
56. Jeng, Y.Y.; Lin, N.T.; Chang, P.H.; Huang, Y.P.; Pang, V.F.; Liu, C.H.; Lin, C.T. Retinal ischemic injury rescued by sodium 4- phenylbutyrate in a rat model. Exp. Eye Res., 2007, 84(3), 486-492.
57. Dasgupta, S.; Zhou, Y.; Jana, M.; Banik, N.L.; Pahan, K. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J. Immunol., 2003, 170(7), 3874-3882.
58. Qi, X.; Hosoi, T.; Okuma, Y.; Kaneko, M.; Nomura, Y. Sodium 4- phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol., 2004, 66(4), 899-908.
59. Vanhaecke, T.; Papeleu, P.; Elaut, G.; Rogiers, V. Trichostatin A - like hydroxamate histone deacetylase inhibitors as therapeutic agents: Toxicological point of view. Curr. Med. Chem., 2004, 11(12), 1629-1643.
60. Sng, J.C.G.; Taniura, H.; Yoneda, Y. Inhibition of histone deacetylation by trichostatin A intensifies the transcriptions of neuronal c-fos and c-jun genes after kainate stimulation. Neurosci. Lett., 2005, 386(3), 150-155.
61. Langley, B.; D'annibale, M.A.; Suh, K.; Ayoub, I.; Tolhurst, A.; Bastan, B.; Yang, L.; Ko, B.; Fisher, M.; Cho, S.; Beal, M.F.; Ratan, R.R. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J. Neurosci., 2008, 28(1), 163-176.
62. Camelo, S.; Iglesias, A.H.; Hwang, D.; Due, B.; Ryu, H.; Smith, K.; Gray, S.G.; Imitola, J.; Duran, G.; Assaf, B.; Langley, B.; Khoury, S.J.; Stephanopoulos, G.; De Girolami, U.; Ratan, R.R.; Ferrante, R.J.; Dangond, F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2005, 164(1-2), 10-21.
63. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.Z.; Mills, E.; Berghs, S.C.; Carey, N.; Finn, P.W.; Collins, L.S.; Tumber, A.; Ritchie, J.W.; Jensen, P.B.; Lichenstein, H.S.; Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J., 2008, 409, 581-589.
64. Duvic, M.; Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs, 2007, 16(7), 1111-1120.
65. Richon, V.M. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br. J. Cancer, 2006, 95, S2-S6.
66. Dokmanovic, M.; Marks, P.A. Prospects: Histone deacetylase inhibitors. J. Cell. Biochem., 2005, 96(2), 293-304.
67. Piepers, S.; Veldink, J.H.; De Jong, S.W.; Van Der Tweel, I.; Van Der Pol, W.L.; Uijtendaal, E.V.; Schelhaas, H.J.; Scheffer, H.; De Visser, M.; De Jong, J.; Wokke, J.H.J.; Groeneveld, G.J.; Van Den Berg, L.H. Randomized Sequential Trial of Valproic Acid in Amyotrophic Lateral Sclerosis. Ann. Neurol., 2009, 66(2), 227-234.
68. Cudkowicz, M.E.; Andres, P.L.; Macdonald, S.A.; Bedlack, R.S.; Choudry, R.; Brown, R.H.; Zhang, H.; Schoenfeld, D.A.; Shefner, J.; Matson, S.; Matson, W.R.; Ferrante, R.J.; Consortium, N.E.A.; Natl, V.a.a.R.C. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral Scler., 2009, 10(2), 99-106.
69. Deb, P.; Sharma, S.; Hassan, K.M. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology, 2010, 17(3), 197-218.
70. Mitsios, N.; Gaffney, J.; Kumar, P.; Krupinski, J.; Kumar, S.; Slevin, M. Pathophysiology of acute ischaemic stroke: An analysis of common signalling mechanisms and identification of new molecular targets. Pathobiology, 2006, 73(4), 159-175.
71. Giffard, R.G.; Yenari, M.A. Many mechanisms for Hsp70 protection from cerebral ischemia. J. Neurosurg. Anesthesiol., 2004, 16(1), 53-61.
72. Ouyang, Y.B.; Giffard, R.G. Cellular neuroprotective mechanisms in cerebral ischemia: Bcl-2 family proteins and protection of mitochondrial function. Cell Calcium, 2004, 36(3-4), 303-311.
73. Paschen, W.; Mengesdorf, T. Cellular abnormalities linked to endoplasmic reticulum dysfunction in cerebrovascular disease - therapeutic potential. Pharmacol. Ther., 2005, 108(3), 362-375.
74. Silacci, P.; Mazzolai, L.; Gauci, C.; Stergiopulos, N.; Yin, H.L.; Hayoz, D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell. Mol. Life Sci., 2004, 61(19-20), 2614-2623.
75. Harms, C.; Bosel, J.; Lautenschlager, M.; Harms, U.; Braun, J.S.; Hortnagl, H.; Dirnagl, U.; Kwiatkowski, D.J.; Fink, K.; Endres, M. Neuronal gelsolin prevents apoptosis by enhancing actin depolymerization. Mol. Cell. Neurosci., 2004, 25(1), 69-82.
76. Meisel, A.; Harms, C.; Yildirim, F.; Bosel, J.; Kronenberg, G.; Harms, U.; Fink, K.B.; Endres, M. Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J. Neurochem., 2006, 98(4), 1019-1031.
77. Aktas, O.; Ullrich, O.; Infante-Duarte, C.; Nitsch, R.; Zipp, F. Neuronal damage in brain inflammation. Arch. Neurol., 2007, 64(2), 185-189.
78. Kleinig, T.J.; Vink, R. Suppression of inflammation in ischemic and hemorrhagic stroke: therapeutic options. Curr. Opin. Neurol., 2009, 22(3), 294-301.
79. Peng, G.S.; Li, G.R.; Tzeng, N.S.; Chen, P.S.; Chuang, D.M.; Hsu, Y.D.; Yang, S.F.; Hong, J.S. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Mol. Brain Res., 2005, 134(1), 162-169.
80. Kim, H.S.; Whang, S.Y.; Woo, M.S.; Park, J.S.; Kim, W.K.; Han, I.O. Sodium butyrate suppresses interferon-gamma-, but not lipopolysaccharide-mediated induction of nitric oxide and tumor necrosis factor-alpha in microglia. J. Neuroimmunol., 2004, 151(1-2), 85-93.
81. Park, J.S.; Woo, M.S.; Kim, S.Y.; Kim, W.K.; Kim, H.S. Repression of interferon-gamma-induced inducible nitric oxide synthase (iNOS) gene expression in microglia by sodium butyrate is mediated through specific inhibition of ERK signaling pathways. J. Neuroimmunol., 2005, 168(1-2), 56-64.
82. Huuskonen, J.; Suuronen, T.; Nuutinen, T.; Kyrylenko, S.; Salminen, A. Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br. J. Pharmacol., 2004, 141(5), 874-880.
83. Niu, F.; Zhang, X.; Chang, L.; Wu, J.; Yu, Y.; Chen, J.; Xu, Y. Trichostatin A enhances OGD-astrocyte viability by inhibiting inflammatory reaction mediated by NF-kappa B. Brain Res. Bull., 2009, 78(6), 342-346.
84. Leker, R.R.; Shohami, E. Cerebral ischemia and trauma - different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res.Rev., 2002, 39(1), 55-73.
85. Sugai, F.; Yamamoto, Y.; Miyaguchi, K.; Zhou, Z.W.; Sumi, H.; Hamasaki, T.; Goto, M.; Sakoda, S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci., 2004, 20(11), 3179-3183.
86. Ragancokova, D.; Song, Y.; Nau, H.; Dengler, R.; Krampfl, K.; Petri, S. Modulation of synaptic transmission and analysis of neuroprotective effects of valproic Acid and derivates in rat embryonic motoneurons. Cell. Mol. Neurobiol., 2010, 30(6), 891-900.
87. Leng, Y.; Liang, M.H.; Ren, M.; Marinova, Z.; Leeds, P.; Chuang, D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: Roles of glycogen synthase kinase-3 inhibition. J. Neurosci., 2008, 28(10), 2576-2588.
88. Wu, J.Y.; Niu, F.N.; Huang, R.; Xu, Y. Enhancement of glutamate uptake in 1-methyl-4-phenylpyridinium-treated astrocytes by trichostatin A. Neuroreport, 2008, 19(12), 1209-1212.
89. Allen, C.L.; Bayraktutan, U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke, 2009, 4(6), 461-470.
90. Ryu, H.; Lee, J.; Olofsson, B.A.; Mwidau, A.; Deodoglu, A.; Escudero, M.; Flemington, E.; Azizkhan-Clifford, J.; Ferrante, R.J.; Ratan, R.R. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. USA, 2003, 100(7), 4281-4286.
91. Marinova, Z.; Ren, M.; Wendland, J.R.; Leng, Y.; Liang, M.H.; Yasuda, S.; Leeds, P.; Chuang, D.M. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J. Neurochem., 2009, 111(4), 976-987.
92. Rouaux, C.; Panteleeva, I.; Rene, F.; De Aguilar, J.L.G.; Echaniz-Laguna, A.; Dupuis, L.; Menger, Y.; Boutillier, A.L.; Loeffler, J.P. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci., 2007, 27(21), 5535-5545.
93. Rogalewski, A.; Schneider, A.; Ringelstein, E.B.; Schabitz, W.R. Toward a multimodal neuroprotective treatment of stroke. Stroke, 2006, 37(4), 1129-1136.
94. Tian, F.; Marini, A.M.; Lipsky, R.H. Effects of histone deacetylase inhibitor Trichostatin A on epigenetic changes and transcriptional activation of Bdnf promoter 1 by rat hippocampal neurons. Ann. N. Y. Acad. Sci., 2010, 1199, 186-193.
95. Ishimaru, N.; Fukuchi, M.; Hirai, A.; Chiba, Y.; Tamura, T.; Takahashi, N.; Tabuchi, A.; Tsuda, M.; Shiraishi, M. Differential epigenetic regulation of BDNF and NT-3 genes by trichostatin A and 5-aza-2 '-deoxycytidine in Neuro-2a cells. Biochem. Biophys. Res. Commun., 2010, 394(1), 173-177.
96. Chen, P.S.; Peng, G.S.; Li, G.; Yang, S.; Wu, X.; Wang, C.C.; Wilson, B.; Lu, R.B.; Gean, P.W.; Chuang, D.M.; Hong, J.S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry, 2006, 11(12), 1116-1125.
97. Wu, X.F.; Chen, P.S.; Dallas, S.; Wilson, B.; Block, M.L.; Wang, C.C.; Kinyamu, H.; Lu, N.; Gao, X.; Leng, Y.; Chuang, D.M.; Zhang, W.Q.; Lu, R.B.; Hong, J.S. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol., 2008, 11(8), 1123-1134.
98. Schroeder, F.A.; Lin, C.L.; Crusio, W.E.; Akbarian, S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol. Psychiatry, 2007, 62(1), 55-64.
99. Higashi, M.; Maruta, N.; Bernstein, A.; Ikenaka, K.; Hitoshi, S. Mood stabilizing drugs expand the neural stem cell pool in the adult brain through activation of notch signaling. Stem Cells, 2008, 26(7), 1758-1767.
100. Hsieh, J.; Nakashima, K.; Kuwabara, T.; Mejia, E.; Gage, F.H. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc. Natl. Acad. Sci. USA, 2004, 101(47), 16659-16664.
101. Alexanian, A.R. Epigenetic modifiers promote efficient generation of neural-like cells from bone marrow-derived mesenchymal cells grown in neural environment. J. Cell. Biochem., 2007, 100(2), 362-371.
102. Alexanian, A.R.; Maiman, D.J.; Kurpad, S.N.; Gennarelli, T.A. In Vitro and In Vivo Characterization of Neurally Modified Mesenchymal Stem Cells Induced by Epigenetic Modifiers and Neural Stem Cell Environment. Stem Cells Dev., 2008, 17(6), 1123-1130.
103. Xi, G.H.; Fewel, M.E.; Hua, Y.; Thompson, B.G.; Hoff, J.T.; Keep, R.F. Intracerebral Hemorrhage - Pathophysiology and therapy. Neurocrit. Care, 2004, 1(1), 5-18.
104. Ribo, M.; Grotta, J.C. Latest advances in intracerebral hemorrhage. Curr. Neurol. Neurosci. Rep., 2006, 6(1), 17-22.
105. Wang, J.; Dore, S. Inflammation after intracerebral hemorrhage. J. Cereb. Blood Flow Metab., 2007, 27(5), 894-908.
106. Marinova Z.; Leng, Y.; Leeds, P.; Chuang, D.-M. Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology, 2010, Oct 1.[Epub ahead of print].
107. Gibson, C.L.; Murphy, S.P. Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies. J. Neurochem., 2010. 115(4), 806-813.
108. Dietz, K.C.; Casaccia, P. HDAC inhibitors and neurodegeneration: At the edge between protection and damage. Pharmacol. Res., 2010, 62(1), 11-17.
109. Glauser, T.A.; Cnaan, A.; Shinnar, S.; Hirtz, D.G.; Dlugos, D.; Masur, D.; Clark, P.O.; Capparelli, E.V.; Adamson, P.C.; Childhood Absence Epilepsy, S. Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy. N. Engl. J. Med., 2010, 362(9), 790-799.
110. Bidabadi, E.; Mashouf, M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr. Drugs, 2010, 12(4), 269-275.
111. Sekhar, S.; Kalra, B.; Mendhekar, D.N.; Tekur, U. Efficacy of Sodium Valproate and Haloperidol in the Management of Acute Mania: A Randomized Open-Label Comparative Study. J. Clin. Pharmacol., 2010. 50(6), 688-692.
112. Chang, J.G.; Hsieh-Li, H.M.; Jong, Y.J.; Wang, N.M.; Tsai, C.H.; Li, H. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. USA, 2001. 98(17), 9808-9813.
113. Andreassi, C.; Angelozzi, C.; Tiziano, F.D.; Vitali, T.; De Vincenzi, E.; Boninsegna, A.; Villanova, M.; Bertini, E.; Pini, A.; Neri, G.; Brahe, C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet., 2004, 12(1), 59-65.
114. Avila, A.M.; Burnett, B.G.; Taye, A.A.; Gabanella, F.; Knight, M.A.; Hartenstein, P.; Cizman, Z.; Di Prospero, N.A.; Pellizzoni, L.; Fischbeck, K.H.; Sumner, C.J. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest., 2007, 117(3), 659-671.
115. Camacho, L.H.; Olson, J.; Tong, W.P.; Young, C.W.; Spriggs, D.R.; Malkin, M.G. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest. New Drugs, 2007, 25(2), 131-138.
116. Lin, J.Q.; Gilbert, J.; Rudek, M.A.; Zwiebel, J.A.; Gore, S.; Jiemjit, A.; Zhao, M.; Baker, S.D.; Ambinder, R.F.; Herman, J.G.; Donehower, R.C.; Carducci, M.A. A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors. Clin. Cancer Res., 2009, 15(19), 6241-6249.
117. Wang, Y.; Wang, X.; Liu, L.M.; Wang, X.M. HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci. Lett., 2009, 467(3), 212-216.
118. Kirschbaum, M.; Popplewell, L.; Nademanee, A.P.; Pullarkat, V.; Delioukina, M.; Zain, J.M.; Matsuoka, D.; Pulone, B.; Frankel, P.; Espinoza-Delgado, I.; Forman, S.J.; Gandara, D.; Newman, E. A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. A California Cancer Consortium Study. Blood, 2008, 112(11), 554-555.
119. Duvic, M.; Talpur, R.; Ni, X.; Zhang, C.; Hazarika, P.; Kelly, C.; Chiao, J.H.; Reilly, J.F.; Ricker, J.L.; Richon, V.M.; Frankel, S.R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 2007, 109(1), 31-39.